Upon completion of the video presentation, to finish the activity and claim your credit, please click
here.
This activity has expired, credit is no longer available.
This activity is supported by an educational grant from Celgene and Takeda Oncology.
New Drugs and Novel Mechanisms of Action in Treating Patients with Multiple Myeloma
Jonathan Kaufman, MD
The Winship Cancer Institute of Emory University
Charise Gleason, MSN, NP-BC, AOCNP®
The Winship Cancer Institute of Emory University
Despite the fact that multiple myeloma remains incurable, mean overall survival has improved dramatically as newer game-changing therapies enter the scene. At the same time, treatment decisions are becoming more complex. This educational activity provides indispensable information regarding risk categories, mechanisms of action for newer drugs, appropriate therapeutic options and sequencing, including identification of transplant eligible patients, and the management of toxicities related to newer drug regimens, thus equipping advanced practitioners to provide optimum clinical support for their patients throughout the trajectory of their disease.
These CME/CE/CPE accredited activities are jointly provided by
